Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Cartesian Therapeutics, Inc. (RNAC : NSDQ)
 
 • Company Description   
Cartesian Therapeutics is a clinical-stage company pioneering RNA cell therapies for the treatment of autoimmune diseases. The company's lead asset, Descartes-08, is a potential first-in-class, RNA-engineered chimeric antigen receptor T-cell therapy in Phase 2b clinical development for patients with generalized myasthenia gravis. Cartesian Therapeutics, formerly known as Selecta Biosciences Inc., is based in WATERTOWN, Mass.

Number of Employees: 66

 
 • Price / Volume Information   
Yesterday's Closing Price: $7.87 Daily Weekly Monthly
20 Day Moving Average: 156,580 shares
Shares Outstanding: 26.00 (millions)
Market Capitalization: $204.65 (millions)
Beta: 0.45
52 Week High: $26.50
52 Week Low: $5.98
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -15.56% -17.77%
12 Week -30.54% -33.42%
Year To Date -56.06% -61.59%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
7495 New Horizon Way
-
Frederick,MD 21703
USA		 ph: 301-348-8698
fax: 617-924-3454		 megan.leduc@cartesiantx.com http://www.cartesiantherapeutics.com
 
 • General Corporate Information   
Officers
Carsten Brunn - President and Chief Executive Officer; and Directo
Blaine Davis - Chief Financial Officer
Carrie S. Cox - Director
Timothy C. Barabe - Director
Nishan de Silva - Director

Peer Information
Cartesian Therapeutics, Inc. (CORR.)
Cartesian Therapeutics, Inc. (RSPI)
Cartesian Therapeutics, Inc. (CGXP)
Cartesian Therapeutics, Inc. (BGEN)
Cartesian Therapeutics, Inc. (GTBP)
Cartesian Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 816212302
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 03/12/26
Share - Related Items
Shares Outstanding: 26.00
Most Recent Split Date: 4.00 (0.03:1)
Beta: 0.45
Market Capitalization: $204.65 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.88 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.27 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 03/12/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 4.27
EPS Growth
vs. Year Ago Period: -100.00%
vs. Previous Quarter: -376.00%
Sales Growth
vs. Year Ago Period: 16.80%
vs. Previous Quarter: 51.68%
ROE
09/30/25 - -
06/30/25 - -
03/31/25 - -
ROA
09/30/25 - -11.67
06/30/25 - -6.36
03/31/25 - -7.01
Current Ratio
09/30/25 - -
06/30/25 - 13.33
03/31/25 - 12.34
Quick Ratio
09/30/25 - -
06/30/25 - 13.33
03/31/25 - 12.34
Operating Margin
09/30/25 - -
06/30/25 - -
03/31/25 - -
Net Margin
09/30/25 - -
06/30/25 - -
03/31/25 - -
Pre-Tax Margin
09/30/25 - -
06/30/25 - -3,506.15
03/31/25 - -111.27
Book Value
09/30/25 - -
06/30/25 - -0.10
03/31/25 - -0.84
Inventory Turnover
09/30/25 - -
06/30/25 - -
03/31/25 - -
Debt-to-Equity
09/30/25 - -
06/30/25 - -
03/31/25 - -
Debt-to-Capital
09/30/25 - -
06/30/25 - -
03/31/25 - -
 

Powered by Zacks Investment Research ©